Cynthia Lin, MD
Nephrology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 29
- 7 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: 052514 · 552746 · 552756 · 752582 · El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
29 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lin’s office at (408) 871-3400 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
29 of 29 plans
| Aetna Medicare Eagle (PPO) | Aetna Medicare | Listed | Sep 8, 2026 |
| Aetna Medicare Enhanced (PPO) | Aetna Medicare | Listed | Sep 8, 2026 |
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A66443 · Current
Licensed to practise in California · since 1998 · expires 2028-09-30 · University of Texas Southwestern Medical School at Dallas.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$235,926
Medicare paid this office $235,926 for 490 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 285 | $45,263 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 125 | $43,604 | $106 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 21 | $21,913 | None |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 22 | $21,487 | $265 |
| Dialysis services, 1 physician visit per month (20 years or older) | 25 | $20,861 | $185 |
See all 15 services
| Return visit (30+ min) | 285 | $45,263 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 125 | $43,604 | $106 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 21 | $21,913 | None |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 22 | $21,487 | $265 |
| Dialysis services, 1 physician visit per month (20 years or older) | 25 | $20,861 | $185 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 18 | $20,523 | $311 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 76 | $12,980 | $155 |
| New patient visit (60+ min) | 51 | $9,821 | $193 |
| Hemodialysis procedure with physician evaluation | 46 | $8,404 | $63 |
| Dialysis services, per day, less than full month service (20 years or older) | 15 | $3,368 | $8 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $3,019 | $116 |
| New patient visit (45+ min) | 14 | $1,852 | $132 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $1,490 | $53 |
| Injection of drug or substance under skin or into muscle | 21 | $887 | $14 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 48 | $732 | $15 |
Who their Medicare patients are
490 Original Medicare patients in 2024. Average age 77 · Under 65 7% · 85 and older 25% · Women 44% · Also on Medicaid 20% · Health risk score 3.19. At or below the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 54% · Coronary heart disease 46% · Heart failure 38% · Atrial fibrillation 37% · Cancer 27% · Depression 17% · COPD 16% · Stroke 15% · Dementia 14%.
The office billed $834,265, Medicare allowed $312,046 and paid $235,926; for 11,782 services of 22 kinds; $21,913 of it was for drugs given in the office and $214,013 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 490 | 11,782 | 77 | 3.19 | $834,265 | $235,926 |
| 2023 | 475 | 13,813 | 77 | 3.38 | $919,957 | $296,176 |
| 2022 | 528 | 17,233 | 76 | 3.46 | $1,087,159 | $351,830 |
| 2021 | 393 | 14,932 | 76 | 3.45 | $863,016 | $300,666 |
| 2020 | 352 | 5,965 | 75 | 3.98 | $659,506 | $202,118 |
| 2019 | 343 | 6,171 | 76 | 3.93 | $594,238 | $192,025 |
| 2018 | 310 | 4,700 | 76 | 3.96 | $547,673 | $174,482 |
| 2017 | 324 | 5,704 | 76 | 4.11 | $598,114 | $193,792 |
| 2016 | 353 | 5,832 | 75 | 3.83 | $627,777 | $206,629 |
| 2015 | 317 | 6,808 | 76 | 3.74 | $616,875 | $213,336 |
| 2014 | 347 | 8,186 | 76 | 3.85 | $622,970 | $213,980 |
| 2013 | 310 | 13,314 | 75 | 4.00 | $703,430 | $234,233 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Dialysis services, 2-3 physician visits per month (20 years or older) | 38 | $47,709 | $274 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 115 | $46,334 | $109 |
| Return visit (30+ min) | 258 | $41,759 | $78 |
| Dialysis services, 1 physician visit per month (20 years or older) | 35 | $31,439 | $191 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 21 | $26,115 | None |
| Home dialysis services per month (20 years or older) | 15 | $25,738 | $274 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 23 | $23,009 | $329 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 77 | $13,351 | $157 |
| New patient visit (60+ min) | 51 | $10,516 | $206 |
| Hemodialysis procedure with physician evaluation | 40 | $8,608 | $65 |
| Dialysis services, per day, less than full month service (20 years or older) | 21 | $6,665 | $9 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,971 | $119 |
| New patient visit (45+ min) | 21 | $2,912 | $139 |
| Telephone medical discussion with physician, 21-30 minutes | 22 | $1,975 | $73 |
| Injection of drug or substance under skin or into muscle | 21 | $1,129 | $14 |
| Short return visit (20+ min) | 12 | $796 | $66 |
2022: 14 services
| Dialysis services, 1 physician visit per month (20 years or older) | 64 | $58,142 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 182 | $54,913 | $94 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 38 | $47,647 | $280 |
| Return visit (30+ min) | 251 | $42,976 | $85 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 21 | $36,842 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 152 | $32,693 | $182 |
| Home dialysis services per month (20 years or older) | 17 | $28,890 | $273 |
| New patient visit (60+ min) | 67 | $12,917 | $193 |
| Hemodialysis procedure with physician evaluation | 61 | $11,720 | $67 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 13 | $7,039 | $335 |
| Telephone medical discussion with physician, 21-30 minutes | 54 | $6,732 | $91 |
| Dialysis procedure requiring repeat evaluation | 11 | $4,496 | $115 |
| Dialysis procedure including 1 evaluation | 13 | $2,780 | $82 |
| Injection of drug or substance under skin or into muscle | 21 | $1,356 | $14 |
2021: 11 services
| Return visit (30+ min) | 186 | $52,950 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $46,943 | $95 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 34 | $44,182 | $281 |
| Dialysis services, 1 physician visit per month (20 years or older) | 51 | $35,387 | $194 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 22 | $34,154 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 99 | $24,110 | $185 |
| Home dialysis services per month (20 years or older) | 12 | $22,001 | $268 |
| New patient visit (60+ min) | 72 | $15,195 | $211 |
| Hemodialysis procedure with physician evaluation | 57 | $9,470 | $68 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | $2,818 | $108 |
| Injection of drug or substance under skin or into muscle | 23 | $1,423 | $14 |
2020: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 150 | $42,298 | $96 |
| Dialysis services, 1 physician visit per month (20 years or older) | 44 | $34,255 | $175 |
| Return visit (30+ min) | 137 | $24,676 | $90 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 28 | $20,537 | $223 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $18,759 | $186 |
| Hemodialysis procedure with physician evaluation | 63 | $14,860 | $67 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $12,892 | None |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 16 | $7,978 | $266 |
| New patient visit (60+ min) | 30 | $5,555 | $185 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,903 | $106 |
| Injection of drug or substance under skin or into muscle | 11 | $761 | $14 |
2019: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 134 | $36,842 | $95 |
| Return visit (30+ min) | 150 | $34,743 | $99 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 23 | $21,581 | $222 |
| Dialysis services, 1 physician visit per month (20 years or older) | 31 | $21,509 | $173 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 89 | $18,058 | $184 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 18 | $16,089 | $264 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $13,894 | None |
| New patient visit (60+ min) | 50 | $9,622 | $192 |
| Hemodialysis procedure with physician evaluation | 51 | $8,795 | $67 |
| Injection of drug or substance under skin or into muscle | 11 | $869 | $17 |
2018: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 153 | $52,334 | $93 |
| Return visit (30+ min) | 121 | $29,706 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 94 | $19,360 | $179 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 18 | $18,326 | $218 |
| Dialysis services, 1 physician visit per month (20 years or older) | 25 | $14,786 | $170 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 13 | $13,918 | $258 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $9,788 | None |
| New patient visit (60+ min) | 33 | $5,960 | $181 |
| Hemodialysis procedure with physician evaluation | 30 | $4,156 | $65 |
| Injection of drug or substance under skin or into muscle | 11 | $865 | $21 |
2017: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 164 | $64,969 | $93 |
| Return visit (30+ min) | 126 | $31,019 | $95 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 19 | $19,232 | $216 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $18,492 | $181 |
| Dialysis services, 1 physician visit per month (20 years or older) | 22 | $16,693 | $169 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 16 | $14,676 | $257 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 16 | $12,107 | None |
| New patient visit (60+ min) | 40 | $6,921 | $173 |
| Hemodialysis procedure with physician evaluation | 25 | $3,541 | $64 |
| Injection of drug or substance under skin or into muscle | 16 | $1,343 | $25 |
2016: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 186 | $67,035 | $93 |
| Return visit (30+ min) | 125 | $29,683 | $94 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 21 | $24,486 | $258 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 27 | $22,386 | $217 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 99 | $19,108 | $180 |
| Dialysis services, 1 physician visit per month (20 years or older) | 20 | $16,178 | $169 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 14 | $13,326 | None |
| New patient visit (60+ min) | 37 | $6,763 | $183 |
| Injection of drug or substance under skin or into muscle | 14 | $1,343 | $25 |
2015: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 156 | $58,541 | $93 |
| Return visit (30+ min) | 134 | $30,255 | $95 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 23 | $29,113 | $258 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 29 | $22,606 | $217 |
| Dialysis services, 1 physician visit per month (20 years or older) | 27 | $17,215 | $169 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13 | $16,168 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 78 | $15,017 | $181 |
| New patient visit (60+ min) | 46 | $8,219 | $179 |
| Hemodialysis procedure with physician evaluation | 31 | $5,730 | $64 |
| Injection of drug or substance under skin or into muscle | 13 | $1,494 | $24 |
2014: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 204 | $89,740 | $92 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 22 | $24,657 | $257 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 32 | $24,292 | $217 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 19 | $18,558 | None |
| Dialysis services, 1 physician visit per month (20 years or older) | 30 | $17,632 | $168 |
| Return visit (30+ min) | 103 | $16,408 | $90 |
| New patient visit (60+ min) | 38 | $6,912 | $182 |
| Short return visit (20+ min) | 82 | $6,900 | $67 |
| Injection of drug or substance under skin or into muscle | 19 | $1,818 | $25 |
2013: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 186 | $96,528 | $90 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 25 | $30,779 | None |
| Return visit (30+ min) | 118 | $28,880 | $96 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 19 | $25,972 | $252 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 22 | $19,597 | $211 |
| Dialysis services, 1 physician visit per month (20 years or older) | 25 | $16,482 | $165 |
| New patient visit (60+ min) | 28 | $5,227 | $187 |
| Injection of drug or substance under skin or into muscle | 25 | $2,586 | $26 |
Medicaid work
$339 in 2023
Medicaid paid $339 for 12 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 12 | $339 |
| 2023 | 12 | 1 | 12 | $339 |
| 2022 | 66 | 1 | 12 | $960 |
See the largest Medicaid services in earlier years
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 66 | $960 |
Drugs they prescribed that Part D paid
$326,086
Pharmacies billed $326,086 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (21 of 2,478) in 2024. Above the middle of the specialty; the typical nephrology clinician is at 0%.
2,172 generic and 275 brand-name prescriptions · $326,086 in drug cost · 21 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Farxiga | 40 | $47,630 | $1,191 |
| Jardiance | 29 | $43,452 | $1,498 |
| Kerendia | 20 | $20,823 | $1,041 |
| Lokelma | 19 | $17,913 | $943 |
| Sevelamer Carbonate | 57 | $16,537 | $290 |
See all 50 drugs
| Farxiga | 40 | $47,630 | $1,191 |
| Jardiance | 29 | $43,452 | $1,498 |
| Kerendia | 20 | $20,823 | $1,041 |
| Lokelma | 19 | $17,913 | $943 |
| Sevelamer Carbonate | 57 | $16,537 | $290 |
| Rybelsus | 12 | $10,877 | $906 |
| Potassium Chloride | 29 | $6,320 | $218 |
| Atorvastatin | 171 | $2,018 | $12 |
| Losartan | 185 | $1,904 | $10 |
| Cinacalcet | 45 | $1,727 | $38 |
| Potassium Citrate Er | 16 | $1,513 | $95 |
| Nano 2nd Gen Pen Needle | 16 | $1,371 | $86 |
| Amlodipine Besylate | 185 | $1,366 | $7 |
| Metoprolol | 95 | $1,332 | $14 |
| Rosuvastatin | 35 | $1,307 | $37 |
| Furosemide | 139 | $1,205 | $9 |
| Allopurinol | 78 | $1,166 | $15 |
| Midodrine | 14 | $937 | $67 |
| Nifedipine Er | 20 | $912 | $46 |
| Hydralazine | 32 | $906 | $28 |
| Valsartan | 20 | $770 | $38 |
| Clonidine | 29 | $747 | $26 |
| Calcium Acetate | 12 | $746 | $62 |
| Calcitriol | 39 | $686 | $18 |
| Lisinopril | 83 | $657 | $8 |
| Olmesartan Medoxomil | 14 | $599 | $43 |
| Carvedilol | 52 | $572 | $11 |
| Levothyroxine | 43 | $539 | $13 |
| Triamterene-Hydrochlorothiazid | 18 | $533 | $30 |
| Gabapentin | 29 | $500 | $17 |
| Chlorthalidone | 25 | $496 | $20 |
| Metoprolol | 55 | $465 | $8 |
| Tamsulosin | 48 | $434 | $9 |
| Atenolol | 25 | $426 | $17 |
| Glipizide | 25 | $373 | $15 |
| Glipizide Er | 25 | $370 | $15 |
| Prednisone | 42 | $349 | $8 |
| Pantoprazole | 14 | $337 | $24 |
| Finasteride | 13 | $217 | $17 |
| Bumetanide | 11 | $207 | $19 |
| Hydrocodone-Acetaminophen | 18 | $169 | $9 |
| Zolpidem | 35 | $125 | $4 |
| Benazepril | 14 | $117 | $8 |
| Isosorbide Mononitrate Er | 23 | $111 | $5 |
| Simvastatin | 14 | $107 | $8 |
| Hydrochlorothiazide | 32 | $96 | $3 |
| Losartan-Hydrochlorothiazide | 17 | $89 | $5 |
| Clonazepam | 12 | $72 | $6 |
| Lorazepam | 13 | $68 | $5 |
| Hydroxyzine Pamoate | 12 | $43 | $4 |
Year by year
| 2024 | 2,478 | 271 | 1% (21) | 11% | $326,086 |
| 2023 | 2,330 | 267 | 1% (14) | 10% | $330,876 |
| 2022 | 2,105 | 265 | 2% (33) | 12% | $267,230 |
| 2021 | 1,580 | 216 | 2% (23) | 9% | $188,732 |
| 2020 | 1,245 | 162 | 2% (24) | None | $211,990 |
| 2019 | 1,192 | 154 | None | 14% | $174,129 |
| 2018 | 1,301 | 152 | 1% (17) | 16% | $191,675 |
| 2017 | 1,299 | 144 | 4% (51) | 22% | $302,457 |
| 2016 | 1,462 | 148 | 3% (42) | 22% | $343,405 |
| 2015 | 1,409 | 138 | 2% (21) | 27% | $290,622 |
| 2014 | 1,135 | 158 | 2% (23) | 26% | $163,544 |
| 2013 | 1,192 | 169 | 4% (42) | 26% | $154,207 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 51 drugs
| Velphoro | 15 | $61,410 | $4,094 |
| Sevelamer Carbonate | 80 | $42,576 | $532 |
| Jardiance | 16 | $27,275 | $1,705 |
| Farxiga | 21 | $21,316 | $1,015 |
| Cinacalcet | 16 | $7,506 | $469 |
| Lantus Solostar | 15 | $5,695 | $380 |
| Prosol | 29 | $4,068 | $140 |
| Potassium Chloride | 26 | $3,805 | $146 |
| Potassium Citrate Er | 18 | $2,926 | $163 |
| Calcium Acetate | 25 | $2,731 | $109 |
| Losartan | 165 | $2,427 | $15 |
| Amlodipine Besylate | 180 | $2,116 | $12 |
| Metoprolol | 102 | $2,002 | $20 |
| Atorvastatin | 139 | $1,821 | $13 |
| Metolazone | 18 | $1,785 | $99 |
| Furosemide | 131 | $1,645 | $13 |
| Allopurinol | 79 | $1,552 | $20 |
| Rosuvastatin | 26 | $1,379 | $53 |
| Hydralazine | 50 | $1,318 | $26 |
| Valsartan | 25 | $1,157 | $46 |
| Nifedipine Er | 18 | $978 | $54 |
| Olmesartan Medoxomil | 16 | $938 | $59 |
| Midodrine | 12 | $907 | $76 |
| Chlorthalidone | 26 | $855 | $33 |
| Calcitriol | 22 | $768 | $35 |
| Tamsulosin | 41 | $745 | $18 |
| Mirtazapine | 16 | $732 | $46 |
| Metoprolol | 50 | $715 | $14 |
| Gabapentin | 36 | $673 | $19 |
| Lisinopril | 76 | $637 | $8 |
| Enalapril Maleate | 15 | $628 | $42 |
| Carvedilol | 39 | $572 | $15 |
| Glipizide Er | 23 | $538 | $23 |
| Clonidine | 24 | $537 | $22 |
| Levothyroxine | 35 | $502 | $14 |
| Pantoprazole | 26 | $466 | $18 |
| Prednisone | 42 | $393 | $9 |
| Hydrocodone-Acetaminophen | 11 | $390 | $35 |
| Atenolol | 26 | $354 | $14 |
| Benazepril | 16 | $299 | $19 |
| Lorazepam | 23 | $282 | $12 |
| Simvastatin | 11 | $276 | $25 |
| Zolpidem | 38 | $274 | $7 |
| Triamterene-Hydrochlorothiazid | 16 | $263 | $16 |
| Glipizide | 18 | $235 | $13 |
| Famotidine | 14 | $205 | $15 |
| Clopidogrel | 12 | $205 | $17 |
| Isosorbide Mononitrate Er | 19 | $141 | $7 |
| Hydrochlorothiazide | 30 | $88 | $3 |
| Pravastatin | 14 | $64 | $5 |
| Hydroxyzine Pamoate | 12 | $31 | $3 |
2022: 45 drugs
| Velphoro | 18 | $55,743 | $3,097 |
| Sevelamer Carbonate | 108 | $42,626 | $395 |
| Prosol | 71 | $9,893 | $139 |
| Cinacalcet | 15 | $6,176 | $412 |
| Lantus Solostar | 17 | $4,592 | $270 |
| Metoprolol | 106 | $3,463 | $33 |
| Calcium Acetate | 15 | $2,465 | $164 |
| Amlodipine Besylate | 176 | $2,405 | $14 |
| Losartan | 137 | $2,287 | $17 |
| Valsartan | 19 | $1,837 | $97 |
| Hydralazine | 62 | $1,831 | $30 |
| Furosemide | 131 | $1,712 | $13 |
| Allopurinol | 69 | $1,707 | $25 |
| Metolazone | 17 | $1,601 | $94 |
| Atorvastatin | 92 | $1,363 | $15 |
| Bumetanide | 18 | $1,199 | $67 |
| Calcitriol | 30 | $853 | $28 |
| Metoprolol | 48 | $844 | $18 |
| Potassium Chloride | 17 | $821 | $48 |
| Nifedipine Er | 13 | $771 | $59 |
| Hydrocodone-Acetaminophen | 24 | $669 | $28 |
| Clonidine | 17 | $553 | $33 |
| Rosuvastatin | 17 | $510 | $30 |
| Lisinopril | 53 | $507 | $10 |
| Carvedilol | 28 | $497 | $18 |
| Zolpidem | 41 | $426 | $10 |
| Benazepril | 17 | $416 | $24 |
| Tamsulosin | 37 | $413 | $11 |
| Levothyroxine | 18 | $401 | $22 |
| Gabapentin | 21 | $398 | $19 |
| Chlorthalidone | 12 | $332 | $28 |
| Pantoprazole | 17 | $312 | $18 |
| Glipizide Er | 13 | $295 | $23 |
| Terazosin | 16 | $256 | $16 |
| Isosorbide Mononitrate Er | 23 | $243 | $11 |
| Prednisone | 28 | $237 | $8 |
| Clonazepam | 16 | $177 | $11 |
| Hydrochlorothiazide | 25 | $155 | $6 |
| Atenolol | 13 | $147 | $11 |
| Glipizide | 16 | $118 | $7 |
| Triamcinolone Acetonide | 12 | $116 | $10 |
| Famotidine | 12 | $109 | $9 |
| Lorazepam | 21 | $82 | $4 |
| Simvastatin | 12 | $71 | $6 |
| Sertraline | 11 | $48 | $4 |
2021: 35 drugs
| Renvela | 13 | $65,255 | $5,020 |
| Sevelamer Carbonate | 61 | $14,297 | $234 |
| Cinacalcet | 14 | $13,981 | $999 |
| Metoprolol | 108 | $3,419 | $32 |
| Potassium Chloride | 20 | $2,775 | $139 |
| Clinisol | 13 | $2,529 | $195 |
| Amlodipine Besylate | 162 | $2,262 | $14 |
| Calcium Acetate | 20 | $2,101 | $105 |
| Losartan | 118 | $1,748 | $15 |
| Atorvastatin | 79 | $1,726 | $22 |
| Hydralazine | 49 | $1,381 | $28 |
| Furosemide | 90 | $1,206 | $13 |
| Bumetanide | 23 | $1,123 | $49 |
| Synthroid | 12 | $1,057 | $88 |
| Allopurinol | 47 | $1,036 | $22 |
| Metolazone | 13 | $1,003 | $77 |
| Enalapril Maleate | 16 | $582 | $36 |
| Metoprolol | 39 | $555 | $14 |
| Hydrocodone-Acetaminophen | 15 | $481 | $32 |
| Glipizide Er | 23 | $451 | $20 |
| Triamterene-Hydrochlorothiazid | 13 | $450 | $35 |
| Levothyroxine | 14 | $443 | $32 |
| Zolpidem | 29 | $441 | $15 |
| Lisinopril | 27 | $414 | $15 |
| Clonidine | 17 | $374 | $22 |
| Carvedilol | 25 | $353 | $14 |
| Chlorthalidone | 18 | $324 | $18 |
| Hydrochlorothiazide | 42 | $279 | $7 |
| Calcitriol | 11 | $231 | $21 |
| Benazepril | 14 | $197 | $14 |
| Prednisone | 16 | $187 | $12 |
| Ramipril | 11 | $176 | $16 |
| Isosorbide Mononitrate Er | 12 | $160 | $13 |
| Quinapril | 11 | $105 | $10 |
| Simvastatin | 22 | $57 | $3 |
2020: 32 drugs
| Renvela | 26 | $111,988 | $4,307 |
| Velphoro | 11 | $26,611 | $2,419 |
| Auryxia | 11 | $15,891 | $1,445 |
| Sevelamer Carbonate | 46 | $9,686 | $211 |
| Uloric | 12 | $3,874 | $323 |
| Metoprolol | 86 | $3,089 | $36 |
| Calcium Acetate | 16 | $1,644 | $103 |
| Losartan | 86 | $1,374 | $16 |
| Amlodipine Besylate | 87 | $1,350 | $16 |
| Bumetanide | 15 | $1,117 | $74 |
| Furosemide | 78 | $1,104 | $14 |
| Potassium Chloride | 24 | $1,088 | $45 |
| Atorvastatin | 67 | $978 | $15 |
| Hydralazine | 37 | $771 | $21 |
| Allopurinol | 43 | $724 | $17 |
| Glipizide Er | 23 | $475 | $21 |
| Chlorthalidone | 14 | $330 | $24 |
| Pantoprazole | 13 | $323 | $25 |
| Hydrocodone-Acetaminophen | 13 | $279 | $21 |
| Hydrochlorothiazide | 46 | $277 | $6 |
| Lisinopril | 23 | $269 | $12 |
| Metoprolol | 28 | $255 | $9 |
| Carvedilol | 18 | $252 | $14 |
| Clonidine | 16 | $245 | $15 |
| Zolpidem | 18 | $212 | $12 |
| Mirtazapine | 14 | $188 | $13 |
| Benazepril | 14 | $178 | $13 |
| Prednisone | 13 | $154 | $12 |
| Quinapril | 12 | $150 | $13 |
| Simvastatin | 21 | $66 | $3 |
| Calcitriol | 13 | $33 | $3 |
| Tramadol | 11 | $27 | $2 |
2019: 26 drugs
| Renvela | 18 | $42,040 | $2,336 |
| Sevelamer Carbonate | 49 | $36,810 | $751 |
| Velphoro | 17 | $30,209 | $1,777 |
| Calcium Acetate | 27 | $5,294 | $196 |
| Metoprolol | 86 | $2,930 | $34 |
| Humulin 70-30 | 11 | $2,689 | $244 |
| Prosol | 12 | $2,310 | $192 |
| Amlodipine Besylate | 97 | $1,619 | $17 |
| Furosemide | 89 | $1,193 | $13 |
| Hydralazine | 45 | $1,189 | $26 |
| Losartan | 92 | $1,153 | $13 |
| Allopurinol | 40 | $957 | $24 |
| Atorvastatin | 66 | $945 | $14 |
| Potassium Chloride | 12 | $386 | $32 |
| Glipizide Er | 15 | $315 | $21 |
| Pantoprazole | 22 | $278 | $13 |
| Simvastatin | 27 | $259 | $10 |
| Lisinopril | 22 | $228 | $10 |
| Hydrochlorothiazide | 28 | $209 | $7 |
| Levothyroxine | 11 | $209 | $19 |
| Clonidine | 15 | $205 | $14 |
| Benazepril | 15 | $169 | $11 |
| Metoprolol | 23 | $162 | $7 |
| Prednisone | 13 | $119 | $9 |
| Tamsulosin | 13 | $86 | $7 |
| Alendronate | 13 | $59 | $5 |
2018: 31 drugs
| Renvela | 27 | $65,212 | $2,415 |
| Sevelamer Carbonate | 40 | $38,033 | $951 |
| Spiriva | 12 | $5,550 | $462 |
| Prosol | 21 | $3,919 | $187 |
| Calcium Acetate | 22 | $3,853 | $175 |
| Metoprolol | 106 | $3,410 | $32 |
| Humulin 70-30 | 11 | $2,669 | $243 |
| Amlodipine Besylate | 118 | $1,586 | $13 |
| Allopurinol | 40 | $971 | $24 |
| Propranolol Hcl Er | 13 | $926 | $71 |
| Losartan | 87 | $845 | $10 |
| Atorvastatin | 49 | $805 | $16 |
| Furosemide | 81 | $578 | $7 |
| Hydrocodone-Acetaminophen | 16 | $496 | $31 |
| Glipizide Er | 16 | $474 | $30 |
| Hydralazine | 30 | $439 | $15 |
| Minoxidil | 17 | $407 | $24 |
| Lisinopril | 30 | $277 | $9 |
| Prednisone | 41 | $264 | $6 |
| Simvastatin | 39 | $262 | $7 |
| Tamsulosin | 18 | $238 | $13 |
| Pantoprazole | 15 | $168 | $11 |
| Zolpidem | 22 | $148 | $7 |
| Omeprazole | 12 | $146 | $12 |
| Carvedilol | 20 | $143 | $7 |
| Clonidine | 14 | $128 | $9 |
| Metoprolol | 28 | $125 | $4 |
| Lorazepam | 13 | $95 | $7 |
| Atenolol | 11 | $86 | $8 |
| Mirtazapine | 11 | $72 | $7 |
| Alendronate | 14 | $66 | $5 |
2017: 28 drugs
| Renvela | 68 | $121,237 | $1,783 |
| Sensipar | 41 | $113,131 | $2,759 |
| Calcium Acetate | 17 | $4,276 | $252 |
| Metoprolol | 96 | $2,878 | $30 |
| Humulin 70-30 | 14 | $2,868 | $205 |
| Amlodipine Besylate | 94 | $971 | $10 |
| Atorvastatin | 44 | $802 | $18 |
| Allopurinol | 32 | $727 | $23 |
| Minoxidil | 28 | $685 | $24 |
| Hydrocodone-Acetaminophen | 33 | $640 | $19 |
| Hydralazine | 29 | $493 | $17 |
| Potassium Chloride | 14 | $454 | $32 |
| Glipizide Er | 14 | $414 | $30 |
| Losartan | 48 | $413 | $9 |
| Furosemide | 49 | $385 | $8 |
| Levothyroxine | 12 | $369 | $31 |
| Tamsulosin | 19 | $319 | $17 |
| Lisinopril | 44 | $311 | $7 |
| Prednisone | 25 | $238 | $10 |
| Simvastatin | 41 | $209 | $5 |
| Clonidine | 23 | $177 | $8 |
| Benazepril | 19 | $170 | $9 |
| Pantoprazole | 15 | $112 | $7 |
| Cyclobenzaprine | 12 | $112 | $9 |
| Zolpidem | 17 | $105 | $6 |
| Gabapentin | 13 | $89 | $7 |
| Hydrochlorothiazide | 14 | $87 | $6 |
| Metoprolol | 21 | $83 | $4 |
2016: 37 drugs
| Sensipar | 73 | $171,772 | $2,353 |
| Renvela | 82 | $124,742 | $1,521 |
| Clinisol | 25 | $4,098 | $164 |
| Calcium Acetate | 21 | $3,221 | $153 |
| Metoprolol | 98 | $2,533 | $26 |
| Humulin 70-30 | 12 | $2,294 | $191 |
| Allopurinol | 40 | $915 | $23 |
| Amlodipine Besylate | 101 | $873 | $9 |
| Atorvastatin | 40 | $830 | $21 |
| Hydrocodone-Acetaminophen | 34 | $795 | $23 |
| Losartan | 61 | $709 | $12 |
| Tamsulosin | 29 | $659 | $23 |
| Potassium Chloride | 22 | $546 | $25 |
| Pioglitazone | 12 | $511 | $43 |
| Minoxidil | 29 | $485 | $17 |
| Hydralazine | 30 | $456 | $15 |
| Levothyroxine | 14 | $418 | $30 |
| Clonidine | 46 | $354 | $8 |
| Glipizide Er | 16 | $332 | $21 |
| Furosemide | 65 | $313 | $5 |
| Doxazosin Mesylate | 13 | $288 | $22 |
| Zolpidem | 11 | $254 | $23 |
| Benazepril | 34 | $252 | $7 |
| Losartan-Hydrochlorothiazide | 22 | $244 | $11 |
| Gabapentin | 24 | $211 | $9 |
| Ramipril | 14 | $188 | $13 |
| Omeprazole | 28 | $161 | $6 |
| Simvastatin | 26 | $157 | $6 |
| Lisinopril | 27 | $155 | $6 |
| Carvedilol | 22 | $155 | $7 |
| Glipizide Xl | 11 | $149 | $14 |
| Prednisone | 19 | $149 | $8 |
| Metoprolol | 20 | $141 | $7 |
| Quinapril | 13 | $127 | $10 |
| Hydrochlorothiazide | 28 | $117 | $4 |
| Temazepam | 12 | $66 | $6 |
| Pantoprazole | 13 | $63 | $5 |
2015: 34 drugs
| Renvela | 78 | $131,192 | $1,682 |
| Sensipar | 67 | $105,804 | $1,579 |
| Metoprolol | 95 | $3,537 | $37 |
| Clinisol | 28 | $3,083 | $110 |
| Clonidine | 19 | $3,066 | $161 |
| Paricalcitol | 12 | $3,016 | $251 |
| Calcium Acetate | 20 | $2,348 | $117 |
| Metolazone | 11 | $1,262 | $115 |
| Tamsulosin | 26 | $1,236 | $48 |
| Atorvastatin | 42 | $879 | $21 |
| Losartan | 84 | $763 | $9 |
| Furosemide | 97 | $684 | $7 |
| Allopurinol | 35 | $645 | $18 |
| Fenofibrate | 12 | $531 | $44 |
| Levothyroxine | 15 | $478 | $32 |
| Amlodipine Besylate | 70 | $387 | $6 |
| Hydralazine | 31 | $359 | $12 |
| Hydrocodone-Acetaminophen | 16 | $344 | $22 |
| Doxazosin Mesylate | 12 | $276 | $23 |
| Potassium Chloride | 14 | $271 | $19 |
| Carvedilol | 44 | $262 | $6 |
| Prednisone | 21 | $211 | $10 |
| Pantoprazole | 19 | $209 | $11 |
| Isosorbide Mononitrate Er | 11 | $198 | $18 |
| Clonidine | 34 | $188 | $6 |
| Lisinopril | 36 | $186 | $5 |
| Minoxidil | 12 | $183 | $15 |
| Omeprazole | 18 | $178 | $10 |
| Ramipril | 22 | $168 | $8 |
| Simvastatin | 15 | $139 | $9 |
| Quinapril | 12 | $119 | $10 |
| Nifedical Xl | 11 | $112 | $10 |
| Atenolol | 24 | $90 | $4 |
| Benazepril | 11 | $53 | $5 |
2014: 31 drugs
| Renvela | 52 | $70,095 | $1,348 |
| Sensipar | 34 | $32,984 | $970 |
| Sevelamer Carbonate | 22 | $16,333 | $742 |
| Levemir | 11 | $2,634 | $239 |
| Calcium Acetate | 15 | $2,572 | $171 |
| Metoprolol | 58 | $2,523 | $44 |
| Losartan | 65 | $1,058 | $16 |
| Atorvastatin | 29 | $774 | $27 |
| Metolazone | 17 | $620 | $36 |
| Levothyroxine | 20 | $517 | $26 |
| Furosemide | 68 | $517 | $8 |
| Lisinopril | 40 | $437 | $11 |
| Amlodipine Besylate | 43 | $421 | $10 |
| Ramipril | 29 | $348 | $12 |
| Hydralazine | 13 | $344 | $26 |
| Allopurinol | 36 | $326 | $9 |
| Carvedilol | 22 | $287 | $13 |
| Doxazosin Mesylate | 11 | $278 | $25 |
| Simvastatin | 26 | $264 | $10 |
| Omeprazole | 13 | $238 | $18 |
| Hydrocodone-Acetaminophen | 18 | $232 | $13 |
| Warfarin | 20 | $214 | $11 |
| Atenolol | 29 | $189 | $7 |
| Insulin | 13 | $157 | $12 |
| Losartan-Hydrochlorothiazide | 12 | $126 | $11 |
| Spironolactone | 14 | $119 | $8 |
| Zolpidem | 14 | $89 | $6 |
| Metoprolol | 14 | $80 | $6 |
| Clonidine | 12 | $79 | $7 |
| Prednisone | 11 | $76 | $7 |
| Gabapentin | 20 | $70 | $4 |
2013: 35 drugs
| Renvela | 44 | $53,150 | $1,208 |
| Sensipar | 38 | $44,129 | $1,161 |
| Calcium Acetate | 31 | $3,855 | $124 |
| Diovan | 18 | $3,649 | $203 |
| Metoprolol | 55 | $2,839 | $52 |
| Lyrica | 12 | $1,867 | $156 |
| Atorvastatin | 29 | $1,210 | $42 |
| Premarin | 12 | $1,020 | $85 |
| Losartan | 48 | $842 | $18 |
| Lisinopril | 59 | $825 | $14 |
| Metolazone | 17 | $795 | $47 |
| Potassium Chloride | 20 | $761 | $38 |
| Amlodipine Besylate | 55 | $761 | $14 |
| Diltiazem 24hr Er | 16 | $608 | $38 |
| Proair Hfa | 11 | $597 | $54 |
| Omeprazole | 17 | $559 | $33 |
| Gabapentin | 18 | $539 | $30 |
| Warfarin | 32 | $520 | $16 |
| Hydralazine | 14 | $464 | $33 |
| Levothyroxine | 22 | $366 | $17 |
| Allopurinol | 44 | $355 | $8 |
| Furosemide | 39 | $346 | $9 |
| Hydrocodone-Acetaminophen | 33 | $326 | $10 |
| Pantoprazole | 14 | $303 | $22 |
| Tamsulosin | 15 | $295 | $20 |
| Sertraline | 12 | $276 | $23 |
| Ramipril | 19 | $262 | $14 |
| Atenolol | 27 | $236 | $9 |
| Losartan-Hydrochlorothiazide | 12 | $137 | $11 |
| Lorazepam | 15 | $127 | $8 |
| Hydrochlorothiazide | 27 | $118 | $4 |
| Metoprolol | 13 | $89 | $7 |
| Ciprofloxacin | 11 | $73 | $7 |
| Prednisone | 13 | $64 | $5 |
| Zolpidem | 11 | $51 | $5 |
Money from drug and device companies
$242 in 2025
| 2025 | 2 | 2 | None | $242 |
| 2024 | 7 | 10 | None | $200 |
| 2023 | 8 | 36 | None | $561 |
| 2022 | 9 | 32 | None | $438 |
| 2021 | 2 | 8 | None | $182 |
| 2020 | 1 | 1 | None | $19 |
| 2019 | 5 | 6 | None | $265 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Apellis Pharmaceuticals | Empaveli | $220 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $23 | 1 payment
|
See all 2 published payments
| Apellis Pharmaceuticals | Meals · 2025-11-05 | Empaveli | $220 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-29 | Farxiga | $23 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $200
| Amgen | Krystexxa | $57 | 2 payments
|
| Fresenius USA Marketing | Velphoro | $34 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $30 | 2 payments
|
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $25 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $23 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $17 | 1 payment
|
| Ardelyx | Ibsrela | $15 | 1 payment
|
2023: $561
| AstraZeneca Pharmaceuticals LP | Lokelma | $145 | 8 payments
|
| Horizon Therapeutics plc | Krystexxa | $138 | 8 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $130 | 10 payments
|
| Otsuka America Pharmaceutical | Jynarque | $51 | 2 payments
|
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $38 | 2 payments
|
| GlaxoSmithKline | Benlysta | $32 | 2 payments
|
| Travere Therapeutics | None | $14 | 3 payments
|
| Mallinckrodt Hospital Products | Acthar | $13 | 1 payment
|
2022: $438
| Horizon Therapeutics plc | Krystexxa | $153 | 13 payments
|
| Fresenius USA Marketing | Velphoro | $118 | 10 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $33 | 1 payment
|
| GlaxoSmithKline | Benlysta | $32 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $31 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $22 | 1 payment
|
| Aurinia Pharma U.S. | Lupkynis | $20 | 1 payment
|
| Xeris Pharmaceuticals | Keveyis | $18 | 1 payment
|
| Travere Therapeutics | None | $12 | 1 payment
|
2021: $182
| Bayer HealthCare Pharmaceuticals | Kerendia | $171 | 7 payments
|
| GlaxoSmithKline | Benlysta | $11 | 1 payment
|
2020: $19
| Otsuka America Pharmaceutical | Jynarque | $19 | 1 payment
|
2019: $265
| Bard Peripheral Vascular | None | $135 | 1 payment
|
| Otsuka America Pharmaceutical | Samsca | $83 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $17 | 1 payment
|
| Akebia Therapeutics | Auryxia | $16 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $15 | 1 payment
|
Professional record
- NPI
- 1134106388
- Licence
- CA A66443California A66443: Current · expires 2028-09-30
- Trained
- University of Texas Southwestern Medical School at Dallas, 1995
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X)
- Mailing address
- 515 South Dr Ste 12, Mountain View, CA, 94040
- NPI first listed
- 2005-12-29
- NPI last updated
- 2025-01-17
- NPI record certified
- 2025-01-17
This is when the NPI record was last certified, not a medical board exam.